首页 > 最新文献

Lancet Microbe最新文献

英文 中文
Used antigenic devices as a matrix for molecular detection of respiratory viruses 使用抗原装置作为呼吸道病毒分子检测的基质。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-01 DOI: 10.1016/S2666-5247(24)00103-4
{"title":"Used antigenic devices as a matrix for molecular detection of respiratory viruses","authors":"","doi":"10.1016/S2666-5247(24)00103-4","DOIUrl":"10.1016/S2666-5247(24)00103-4","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140909507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Need for high-resolution observational cohort studies to understand the natural history of tuberculosis 需要进行高分辨率的队列观察研究,以了解结核病的自然病史。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-01 DOI: 10.1016/S2666-5247(24)00140-X
{"title":"Need for high-resolution observational cohort studies to understand the natural history of tuberculosis","authors":"","doi":"10.1016/S2666-5247(24)00140-X","DOIUrl":"10.1016/S2666-5247(24)00140-X","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141545388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action 实施欧盟抗菌药创新和获取拉动激励机制:行动蓝图
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-01 DOI: 10.1016/S2666-5247(24)00109-5
In June, 2023, the Council of the EU published a recommendation that the European Commission should contribute to the design and governance of an EU cross-country pull incentive to stimulate antimicrobial innovation and access. In this Personal View, we discuss six key considerations to support the implementation of the new pull incentive—ie, the size of the potential pull incentive and possible contributions of the member states, design of the incentive model, interplay of the new pull incentive with the proposed revisions of the EU pharmaceutical legislation, roles and responsibilities of both the EU and member states, balance between pull and push incentives, and global cooperation and responsibility. As the involvement of the member states with the EU pull incentive will be voluntary, member states should have confidence that the processes used to identify eligible antimicrobials, negotiate terms and conditions, and oversee access agreements are transparent, inclusive, and methodologically robust.
2023 年 6 月,欧盟理事会公布了一项建议,即欧盟委员会应参与欧盟跨国拉动激励机制的设计和管理,以刺激抗菌药物的创新和获取。在这篇个人观点中,我们将讨论支持实施新的拉动式激励措施的六个关键考虑因素,即潜在拉动式激励措施的规模和成员国可能的贡献、激励模式的设计、新的拉动式激励措施与欧盟药品立法修订建议的相互作用、欧盟和成员国的角色和责任、拉动式激励措施和推动式激励措施之间的平衡以及全球合作和责任。由于成员国对欧盟拉动激励机制的参与将是自愿的,因此成员国应相信用于确定合格抗菌药物、谈判条款和条件以及监督准入协议的程序是透明的、包容的,并且在方法上是稳健的。
{"title":"Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action","authors":"","doi":"10.1016/S2666-5247(24)00109-5","DOIUrl":"10.1016/S2666-5247(24)00109-5","url":null,"abstract":"<div><div>In June, 2023, the Council of the EU published a recommendation that the European Commission should contribute to the design and governance of an EU cross-country pull incentive to stimulate antimicrobial innovation and access. In this Personal View, we discuss six key considerations to support the implementation of the new pull incentive—ie, the size of the potential pull incentive and possible contributions of the member states, design of the incentive model, interplay of the new pull incentive with the proposed revisions of the EU pharmaceutical legislation, roles and responsibilities of both the EU and member states, balance between pull and push incentives, and global cooperation and responsibility. As the involvement of the member states with the EU pull incentive will be voluntary, member states should have confidence that the processes used to identify eligible antimicrobials, negotiate terms and conditions, and oversee access agreements are transparent, inclusive, and methodologically robust.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141399355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stability of Bas-Congo virus neutralising antibodies in serum samples during long-term storage—Authors’ reply 血清样本中的下刚果病毒中和抗体在长期储存过程中的稳定性--作者的回复。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-01 DOI: 10.1016/S2666-5247(24)00157-5
{"title":"Stability of Bas-Congo virus neutralising antibodies in serum samples during long-term storage—Authors’ reply","authors":"","doi":"10.1016/S2666-5247(24)00157-5","DOIUrl":"10.1016/S2666-5247(24)00157-5","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Environmental surveillance of a circulating vaccine-derived poliovirus type 2 outbreak in Israel between 2022 and 2023: a genomic epidemiology study 对 2022 年至 2023 年以色列爆发的疫苗衍生型 2 型脊髓灰质炎病毒疫情进行环境监测:基因组流行病学研究。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-01 DOI: 10.1016/S2666-5247(24)00116-2
<div><h3>Background</h3><div>Similarly to wild poliovirus, vaccine-derived poliovirus (VDPV) strains can cause acute flaccid paralysis, posing a considerable challenge to public health and the eradication of poliovirus. VDPV outbreaks, particularly VDPV type 2 (VDPV2), are increasing worldwide, including in high-income countries with high vaccine coverage. We aimed to conduct a comprehensive analysis of the molecular epidemiology of a widespread VDPV2 outbreak in Israel in 2022–23 using conventional polio identification techniques and whole-genome sequencing.</div></div><div><h3>Methods</h3><div>In this genomic epidemiology study, we monitored and identified poliovirus type 2 (PV2) through the surveillance of stool samples from individuals with acute flaccid paralysis and related contacts, as well as environmental surveillance of sewage samples. Environmental surveillance involved 15 routine surveillance sites and an additional 30 sites dedicated to monitoring this outbreak, covering approximately 70% of Israel's population between April 1, 2022, and June 30, 2023. Additionally, we performed phylogenetic and mutation analyses using whole-genome, next-generation sequencing of PV2 isolates to identify recombination events, characterise VDPV2 lineages according to the capsid region, and establish the geographical distribution and linkage of PV2 isolates.</div></div><div><h3>Findings</h3><div>We detected 256 genetically linked samples from environmental surveillance, as well as one case of acute flaccid paralysis and four positive contacts associated with the Sabin type 2 oral vaccine strain. Most affected locations showed a high-density population of Jewish Ultra-Orthodox communities. Through high-resolution genomic characterisation and phylogenetic analysis of 202 representative sequences with complete capsid coverage, including isolates from both environmental surveillance and the case of acute flaccid paralysis, a conclusive linkage was established among all detections, confirming them to be part of a single VDPV2 outbreak. This strategy enabled the characterisation of three distinct lineages and established connections between different locations in Israel, including linking the case of acute flaccid paralysis and nearby environmental surveillance detections from the northern region with detections in the geographically distant central region.</div></div><div><h3>Interpretation</h3><div>This study highlights the role of environmental surveillance in the early detection and monitoring of poliovirus circulation, enabling a prompt public health response involving enhanced surveillance and a catch-up campaign with inactivated polio vaccine. Whole-genome sequencing offered valuable insights into the origins of the outbreak, linkage across detections, and the geographical distribution of the virus, with higher resolution than would have been possible with the standard analysis of the <em>VP1</em> gene alone.</div></div><div><h3>Funding</h3><div>None.<
背景:与野生脊髓灰质炎病毒类似,疫苗衍生脊髓灰质炎病毒(VDPV)毒株也可导致急性弛缓性麻痹,这对公共卫生和根除脊髓灰质炎病毒构成了巨大挑战。疫苗衍生脊髓灰质炎病毒(VDPV)疫情,尤其是 2 型疫苗衍生脊髓灰质炎病毒(VDPV2)疫情,正在全球范围内不断增加,包括在疫苗覆盖率较高的高收入国家。我们的目标是利用传统的脊髓灰质炎鉴定技术和全基因组测序技术,对 2022-23 年以色列大范围 VDPV2 型疫情的分子流行病学进行全面分析:在这项基因组流行病学研究中,我们通过监测急性弛缓性麻痹患者和相关接触者的粪便样本以及污水样本的环境监测来监测和鉴定脊髓灰质炎病毒 2 型 (PV2)。在 2022 年 4 月 1 日至 2023 年 6 月 30 日期间,环境监测涉及 15 个常规监测点和另外 30 个专门监测疫情的监测点,覆盖以色列约 70% 的人口。此外,我们还利用 PV2 分离物的全基因组下一代测序技术进行了系统发育和突变分析,以确定重组事件,根据囊膜区域确定 VDPV2 系的特征,并确定 PV2 分离物的地理分布和联系:我们从环境监测中检测到 256 份基因关联样本,以及一例急性弛缓性麻痹病例和四名与 Sabin 2 型口服疫苗株相关的阳性接触者。大多数受影响地区都有高密度的犹太极端正统派社区人口。通过对 202 个具有完整囊盖覆盖范围的代表性序列(包括来自环境监测和急性弛缓性麻痹病例的分离物)进行高分辨率基因组特征描述和系统进化分析,在所有检测物之间建立了确凿的联系,证实它们是单一 VDPV2 爆发的一部分。通过这一策略,确定了三个不同品系的特征,并建立了以色列不同地区之间的联系,包括将北部地区的急性弛缓性麻痹病例和附近的环境监测检测结果与地理位置遥远的中部地区的检测结果联系起来:本研究强调了环境监测在早期发现和监测脊髓灰质炎病毒循环中的作用,从而能够迅速采取公共卫生应对措施,包括加强监测和开展脊髓灰质炎灭活疫苗补种活动。全基因组测序为了解疫情的起源、不同检测结果之间的联系以及病毒的地理分布提供了宝贵的信息,其分辨率高于仅对 VP1 基因进行标准分析的结果:无。
{"title":"Environmental surveillance of a circulating vaccine-derived poliovirus type 2 outbreak in Israel between 2022 and 2023: a genomic epidemiology study","authors":"","doi":"10.1016/S2666-5247(24)00116-2","DOIUrl":"10.1016/S2666-5247(24)00116-2","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Similarly to wild poliovirus, vaccine-derived poliovirus (VDPV) strains can cause acute flaccid paralysis, posing a considerable challenge to public health and the eradication of poliovirus. VDPV outbreaks, particularly VDPV type 2 (VDPV2), are increasing worldwide, including in high-income countries with high vaccine coverage. We aimed to conduct a comprehensive analysis of the molecular epidemiology of a widespread VDPV2 outbreak in Israel in 2022–23 using conventional polio identification techniques and whole-genome sequencing.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;In this genomic epidemiology study, we monitored and identified poliovirus type 2 (PV2) through the surveillance of stool samples from individuals with acute flaccid paralysis and related contacts, as well as environmental surveillance of sewage samples. Environmental surveillance involved 15 routine surveillance sites and an additional 30 sites dedicated to monitoring this outbreak, covering approximately 70% of Israel's population between April 1, 2022, and June 30, 2023. Additionally, we performed phylogenetic and mutation analyses using whole-genome, next-generation sequencing of PV2 isolates to identify recombination events, characterise VDPV2 lineages according to the capsid region, and establish the geographical distribution and linkage of PV2 isolates.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;We detected 256 genetically linked samples from environmental surveillance, as well as one case of acute flaccid paralysis and four positive contacts associated with the Sabin type 2 oral vaccine strain. Most affected locations showed a high-density population of Jewish Ultra-Orthodox communities. Through high-resolution genomic characterisation and phylogenetic analysis of 202 representative sequences with complete capsid coverage, including isolates from both environmental surveillance and the case of acute flaccid paralysis, a conclusive linkage was established among all detections, confirming them to be part of a single VDPV2 outbreak. This strategy enabled the characterisation of three distinct lineages and established connections between different locations in Israel, including linking the case of acute flaccid paralysis and nearby environmental surveillance detections from the northern region with detections in the geographically distant central region.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;div&gt;This study highlights the role of environmental surveillance in the early detection and monitoring of poliovirus circulation, enabling a prompt public health response involving enhanced surveillance and a catch-up campaign with inactivated polio vaccine. Whole-genome sequencing offered valuable insights into the origins of the outbreak, linkage across detections, and the geographical distribution of the virus, with higher resolution than would have been possible with the standard analysis of the &lt;em&gt;VP1&lt;/em&gt; gene alone.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Funding&lt;/h3&gt;&lt;div&gt;None.&lt;","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implications of subclinical tuberculosis for vaccine trial design and global effect 亚临床结核病对疫苗试验设计和全球效应的影响。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-01 DOI: 10.1016/S2666-5247(24)00127-7
Tuberculosis is a leading cause of death from an infectious agent globally. Infectious subclinical tuberculosis accounts for almost half of all tuberculosis cases in national tuberculosis prevalence surveys, and possibly contributes to transmission and might be associated with morbidity. Modelling studies suggest that new tuberculosis vaccines could have substantial health and economic effects, partly based on the assumptions made regarding subclinical tuberculosis. Evaluating the efficacy of prevention of disease tuberculosis vaccines intended for preventing both clinical and subclinical tuberculosis is a priority. Incorporation of subclinical tuberculosis as a composite endpoint in tuberculosis vaccine trials can help to reduce the sample size and duration of follow-up and to evaluate the efficacy of tuberculosis vaccines in preventing clinical and subclinical tuberculosis. Several design options with various benefits, limitations, and ethical considerations are possible in this regard, which would allow for the generation of the evidence needed to estimate the positive global effects of tuberculosis vaccine trials, in addition to informing policy and vaccination strategies.
结核病是全球因传染性病原体致死的主要原因。在国家结核病发病率调查中,传染性亚临床结核病几乎占所有结核病病例的一半,可能会造成传播,也可能与发病率有关。模型研究表明,新的结核病疫苗可能会对健康和经济产生重大影响,这部分是基于对亚临床结核病的假设。评估旨在预防临床和亚临床结核病的结核病预防疫苗的功效是当务之急。将亚临床肺结核作为综合终点纳入结核病疫苗试验,有助于减少样本量和缩短随访时间,并评估结核病疫苗在预防临床和亚临床肺结核方面的疗效。在这方面,有几种设计方案具有不同的益处、局限性和伦理考虑因素,除了为政策和疫苗接种战略提供信息外,还能产生必要的证据来估计结核病疫苗试验的积极全球效应。
{"title":"Implications of subclinical tuberculosis for vaccine trial design and global effect","authors":"","doi":"10.1016/S2666-5247(24)00127-7","DOIUrl":"10.1016/S2666-5247(24)00127-7","url":null,"abstract":"<div><div>Tuberculosis is a leading cause of death from an infectious agent globally. Infectious subclinical tuberculosis accounts for almost half of all tuberculosis cases in national tuberculosis prevalence surveys, and possibly contributes to transmission and might be associated with morbidity. Modelling studies suggest that new tuberculosis vaccines could have substantial health and economic effects, partly based on the assumptions made regarding subclinical tuberculosis. Evaluating the efficacy of prevention of disease tuberculosis vaccines intended for preventing both clinical and subclinical tuberculosis is a priority. Incorporation of subclinical tuberculosis as a composite endpoint in tuberculosis vaccine trials can help to reduce the sample size and duration of follow-up and to evaluate the efficacy of tuberculosis vaccines in preventing clinical and subclinical tuberculosis. Several design options with various benefits, limitations, and ethical considerations are possible in this regard, which would allow for the generation of the evidence needed to estimate the positive global effects of tuberculosis vaccine trials, in addition to informing policy and vaccination strategies.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges and advancements in the development of vaccines and therapies against Chagas disease 开发南美锥虫病疫苗和疗法的挑战与进展。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-01 DOI: 10.1016/j.lanmic.2024.100972
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, presents a substantial global health burden, affecting millions of individuals worldwide and posing a continual risk of infection. Despite the high mortality and morbidity rates, effective vaccines to prevent infection by the parasite remain elusive, and the drugs currently available are suboptimal. Understanding the intricate dynamics of parasite–host interactions and the resulting immune responses, which contribute to both protection and pathology, is crucial for the development of effective vaccines and therapies against Chagas disease. In this Series paper, we discuss the challenges associated with discovering and translating prophylactic and therapeutic strategies from the laboratory bench to clinical application. We highlight ongoing efforts in vaccine and new drug development, with a focus on more advanced candidates for vaccines and drugs. We also discuss potential solutions, emphasising the importance of collaborative research efforts, sustained funding, and a comprehensive understanding of host–parasite interactions and immunopathology to advance the development of new vaccines and therapies against Chagas disease.
恰加斯病是由原生寄生虫克鲁斯锥虫引起的,给全球健康造成了巨大负担,影响着全球数百万人,并带来持续的感染风险。尽管死亡率和发病率都很高,但预防寄生虫感染的有效疫苗仍然遥遥无期,而目前可用的药物也不尽如人意。了解寄生虫与宿主相互作用的复杂动态以及由此产生的免疫反应对保护和病理学都有影响,这对开发有效的恰加斯病疫苗和疗法至关重要。在这篇系列论文中,我们讨论了发现预防和治疗策略并将其从实验室转化为临床应用所面临的挑战。我们重点介绍了疫苗和新药开发方面正在进行的工作,重点是更先进的候选疫苗和药物。我们还讨论了潜在的解决方案,强调了合作研究工作、持续供资以及全面了解宿主与寄生虫相互作用和免疫病理学对于推动南美锥虫病新疫苗和疗法开发的重要性。
{"title":"Challenges and advancements in the development of vaccines and therapies against Chagas disease","authors":"","doi":"10.1016/j.lanmic.2024.100972","DOIUrl":"10.1016/j.lanmic.2024.100972","url":null,"abstract":"<div><div>Chagas disease, caused by the protozoan parasite <em>Trypanosoma cruzi</em>, presents a substantial global health burden, affecting millions of individuals worldwide and posing a continual risk of infection. Despite the high mortality and morbidity rates, effective vaccines to prevent infection by the parasite remain elusive, and the drugs currently available are suboptimal. Understanding the intricate dynamics of parasite–host interactions and the resulting immune responses, which contribute to both protection and pathology, is crucial for the development of effective vaccines and therapies against Chagas disease. In this Series paper, we discuss the challenges associated with discovering and translating prophylactic and therapeutic strategies from the laboratory bench to clinical application. We highlight ongoing efforts in vaccine and new drug development, with a focus on more advanced candidates for vaccines and drugs. We also discuss potential solutions, emphasising the importance of collaborative research efforts, sustained funding, and a comprehensive understanding of host–parasite interactions and immunopathology to advance the development of new vaccines and therapies against Chagas disease.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rapid test using a single drop of blood to screen for schistosomiasis in non-endemic countries 在非血吸虫病流行国家使用一滴血快速检测法筛查血吸虫病。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-01 DOI: 10.1016/S2666-5247(24)00105-8
{"title":"A rapid test using a single drop of blood to screen for schistosomiasis in non-endemic countries","authors":"","doi":"10.1016/S2666-5247(24)00105-8","DOIUrl":"10.1016/S2666-5247(24)00105-8","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141026135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stability of Bas-Congo virus neutralising antibodies in serum samples during long-term storage 血清样本中巴刚果病毒中和抗体在长期储存过程中的稳定性。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-01 DOI: 10.1016/S2666-5247(24)00156-3
{"title":"Stability of Bas-Congo virus neutralising antibodies in serum samples during long-term storage","authors":"","doi":"10.1016/S2666-5247(24)00156-3","DOIUrl":"10.1016/S2666-5247(24)00156-3","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel SARS-CoV-2 recombinant transmitted from a patient with an acute co-infection. 从一名急性合并感染患者身上传播的新型 SARS-CoV-2 重组病毒。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-01 DOI: 10.1016/j.lanmic.2024.100998
Robert Dyrdak, Sofia Stamouli, Shambhu Ganeshappa Aralaguppe, Martin Ekman, Hamzah Safari, Carlo Berg, Elin Movert, Neus Latorre-Margalef, Emmi Andersson, Magnus Gisslén, Joanna Nederby-Öhd, Åsa Sjödin Leufvén, Josette Schoenmakers, Sandra Broddesson, Ben Murrell, Jan Albert
{"title":"A novel SARS-CoV-2 recombinant transmitted from a patient with an acute co-infection.","authors":"Robert Dyrdak, Sofia Stamouli, Shambhu Ganeshappa Aralaguppe, Martin Ekman, Hamzah Safari, Carlo Berg, Elin Movert, Neus Latorre-Margalef, Emmi Andersson, Magnus Gisslén, Joanna Nederby-Öhd, Åsa Sjödin Leufvén, Josette Schoenmakers, Sandra Broddesson, Ben Murrell, Jan Albert","doi":"10.1016/j.lanmic.2024.100998","DOIUrl":"10.1016/j.lanmic.2024.100998","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142376165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lancet Microbe
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1